Abstract
Medical-administrative databases are an important source of big data to assess the epidemiology of diseases and interventions, compare drugs, and investigate rare adverse events. We describe the French national health insurance system databases and the Epidemiology and Safety (EPISAFE) collaboration program in ophthalmology and illustrate the paper with recent studies that used the databases to investigate cataract surgery. The Système national d'information inter-régime de l'assurance maladie (SNIIR-AM) is one of the largest databases of medical and administrative data for a general population, covering nearly 65 million people. The SNIIR-AM database links data for all outpatient-reimbursed health expenditures, hospitalization in all 1,546 French private or public healthcare facilities, and date of death. The use of this database provides information at the scale of the entire country, allowing measurement of the impact of changes in practices and new guidelines. Between 2009 and 2012, a total of 2,717,203 eyes in 1,817,865 patients underwent cataract surgery in France, and the incidence of cataract surgery increased from 9.86 to 11.08/1,000 person-years. The 4-year cumulative risk of retinal detachment was 0.99%, and patients <60 years of age were at higher risk of retinal detachment. The incidence of pseudophakic cystoid macular edema was 0.95%. From 2005 to 2014, from data including more than 6 million procedures, the incidence of endophthalmitis after cataract surgery decreased from 0.15 to 0.05%. The EPISAFE collaboration program encompasses the key issues facing ophthalmology, including public health and public policy concerning disease incidence and prevalence, safety and adverse event monitoring, and clinical guidelines.
References
1.
World Health Organization: Action Plan for the Prevention of Avoidable Blindness and Vision Impairment 2009-2013. WHO, Geneva, 2010.
2.
World Health Organization: Global Initiative for the Elimination of Avoidable Blindness: Action Plan 2006-2011. WHO, Geneva, 2007. http://www.who.int/blindness/Vision2020_report.pdf.
3.
World Health Organization: Universal Eye Health: A Global Action Plan 2014-2019. WHO, Geneva, 2013.
4.
Delcourt C, Korobelnik J-F, Buitendijk GHS, Foster PJ, Hammond CJ, Piermarocchi S, et al: Ophthalmic epidemiology in Europe: the “European Eye Epidemiology” (E3) consortium. Eur J Epidemiol 2016;31:197-210.
5.
Rector TS, Wickstrom SL, Shah M, Thomas Greeenlee N, Rheault P, Rogowski J, et al: Specificity and sensitivity of claims-based algorithms for identifying members of Medicare + Choice health plans that have chronic medical conditions. Health Serv Res 2004;39:1839-1857.
6.
Jameson K, D'Oca K, Leigh P, Murray-Thomas T: Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink. Curr Med Res Opin 2016;32:49-60.
7.
Dixon WG, Abrahamowicz M, Beauchamp M-E, Ray DW, Bernatsky S, Suissa S, et al: Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012;71:1128-1133.
8.
Carlsson AC, Wändell P, Ösby U, Zarrinkoub R, Wettermark B, Ljunggren G: High prevalence of diagnosis of diabetes, depression, anxiety, hypertension, asthma and COPD in the total population of Stockholm, Sweden - a challenge for public health. BMC Public Health 2013;13:670.
9.
Moulis G, Palmaro A, Montastruc J-L, Godeau B, Lapeyre-Mestre M, Sailler L: Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood 2014;124:3308-3315.
10.
Neumann A, Maura G, Weill A, Ricordeau P, Alla F, Allemand H: Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. Pharmacoepidemiol Drug Saf 2014;23:240-250.
11.
Weill A, Dalichampt M, Raguideau F, Ricordeau P, Blotière P-O, Rudant J, et al: Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ 2016;353:i2002.
12.
Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc J-L, Sailler L: Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol 2015;90:301-305.
13.
Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y: French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 2010;58:286-290.
14.
Goldberg M, Jougla E, Fassa M, Padieu R, Quantin C: The French health information system. J Int Assoc Off Stat 2012;28:73-85.
15.
World Health Organization: International Classification of Diseases. http://www.who.int/classifications/icd/en/ (accessed August 2016).
16.
De Roquefueil L, Studer A, Neumann A, Merlière Y: L'échantillon généraliste des bénéficiaires : rerpésentativité, portée et limites. Prat Organ Soins 2009;40:213-223.
17.
Cougnard-Grégoire A, Merle BMJ, Korobelnik J-F, Rougier M-B, Delyfer M-N, Le Goff M, et al: Olive oil consumption and age-related macular degeneration: The Alienor Study. PLoS One 2016;11:e0160240.
18.
Creuzot-Garcher C, Binquet C, Daniel S, Bretillon L, Acar N, de Lazzer A, et al: The Montrachet Study: study design, methodology and analysis of visual acuity and refractive errors in an elderly population. Acta Ophthalmol 2016;94:e90-e97.
19.
Carrière I, Delcourt C, Daien V, Pérès K, Féart C, Berr C, et al: A prospective study of the bi-directional association between vision loss and depression in the elderly. J Affect Disord 2013;151:164-170.
20.
Daien V, Pérès K, Villain M, Colvez A, Delcourt C, Carrière I: Visual impairment, optical correction, and their impact on activity limitations in elderly persons: the POLA study. JAMA Intern Med 2011;171:1206-1207.
21.
Daien V, Le Pape A, Heve D, Carriere I, Villain M: Incidence and characteristics of cataract surgery in France from 2009 to 2012: a national population study. Ophthalmology 2015;122:1633-1638.
22.
Gibson JM, Gibson SJ: A safety evaluation of ranibizumab in the treatment of age-related macular degeneration. Expert Opin Drug Saf 2014;13:1259-1270.
23.
Esen F, Alhan O, Kuru P, Sahin O: Safety assessment and power analyses in published anti-vascular endothelial growth factor randomized controlled trials. Am J Ophthalmol 2016;169:68-72.
24.
Creuzot-Garcher C, Benzenine E, Mariet A-S, de Lazzer A, Chiquet C, Bron AM, et al: Incidence of acute postoperative endophthalmitis after cataract surgery: a nationwide study in France from 2005 to 2014. Ophthalmology 2016;123:1414-1420.
25.
Daien V, Papinaud L, Gillies MC, Domerg C, Nagot N, Lacombe S, et al: Effectiveness and safety of an intracameral injection of cefuroxime for the prevention of endophthalmitis after cataract surgery with or without perioperative capsular rupture. JAMA Ophthalmol 2016;134:810-816.
26.
Institut National de la Statistique et des Etudes Economiques. 2014. http://www.insee.fr/en/bases-de-donnees/default.asp?page=recensements.htm.
27.
Daien V, Le Pape A, Heve D, Carriere I, Villain M: Incidence, risk factors, and impact of age on retinal detachment after cataract surgery in France: a national population study. Ophthalmology 2015;122:2179-2185.
28.
Daien V, Papinaud L, Domerg C, Lacombe S, Daures JP, Villain M: Incidence and characteristics of cystoid macular edema after cataract surgery. Ophthalmology 2016;123:663-664.
29.
Bellan L: The evolution of cataract surgery: the most common eye procedure in older adults. Geriatr Aging 2008;11:328-332.
30.
Coleman AL: How big data informs us about cataract surgery: The LXXII Edward Jackson Memorial Lecture. Am J Ophthalmol 2015;160:1091-1103.e3.
31.
Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, et al: Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology 2015;122:1837-1845.
32.
Day AC, Donachie PHJ, Sparrow JM, Johnston RL; Royal College of Ophthalmologists' National Ophthalmology Database: United Kingdom National Ophthalmology Database study of cataract surgery. Report 3. Pseudophakic retinal detachment. Ophthalmology 2016;123:1711-1715.
33.
Zetterström C, Behndig A, Kugelberg M, Montan P, Lundström M: Changes in intraocular pressure after cataract surgery: analysis of the Swedish National Cataract Register Data. J Cataract Refract Surg 2015;41:1725-1729.
34.
Centre for Evidence-Based-Medicine. http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/2009.
35.
Black N: Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-1218.
36.
Vuillermoz C, Aouba A, Grout L, Vandentorren S, Tassin F, Moreno-Betancur M, et al: Mortality among homeless people in France, 2008-10. Eur J Public Health 2016;26:1028-1033.
37.
Tuppin P, Ricci-Renaud P, de Peretti C, Fagot-Campagna A, Alla F, Danchin N, et al: Frequency of cardiovascular diseases and risk factors treated in France according to social deprivation and residence in an overseas territory. Int J Cardiol 2014;173:430-435.
38.
Goldberg M, Carton M, Gourmelen J, Genreau M, Montourcy M, Le Got S, et al: The opening of the French national health database: opportunities and difficulties. The experience of the Gazel and Constances cohorts (in French). Rev Epidemiol Sante Publique 2016;64:313-320.
39.
García Rodríguez LA, Pérez Gutthann S: Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-425.
40.
Quantin C, Benzenine E, Velten M, Huet F, Farrington CP, Tubert-Bitter P: Self-controlled case series and misclassification bias induced by case selection from administrative hospital databases: application to febrile convulsions in pediatric vaccine pharmacoepidemiology. Am J Epidemiol 2013;178:1731-1739.
41.
Hanf M, Quantin C, Farrington P, Benzenine E, Hocine NM, Velten M, et al: Validation of the French national health insurance information system as a tool in vaccine safety assessment: application to febrile convulsions after pediatric measles/mumps/rubella immunization. Vaccine 2013;31:5856-5862.
42.
Bezin J, Pariente A, Lassalle R, Dureau-Pournin C, Abouelfath A, Robinson P, et al: Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France. Eur J Clin Pharmacol 2014;70:429-436.
43.
Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc J-L, Sailler L: French health insurance databases: what interest for medical research? Rev Med Interne 2015;36:411-417.
44.
Haut Conseil de la Santé Publique: Pour une meilleure utilisation des bases de données administratives et médico-administratives nationales pour la santé publique et la recherche; 2012. http://www.hcsp.fr/explore.cgi/avisrapportsdomaine?clefr=258 (accessed August 2016).
45.
Bras P-L, Loth A: Rapport sur la gouvernance et l'utilisation des données de santé; 2013. http://www.social-sante.gouv.fr/IMG/pdf/Rapportdonneesdesante2013.pdf (accessed August 2016).
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
